Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.040
+0.010 (0.97%)
At close: May 9, 2025, 4:00 PM
1.100
+0.060 (5.77%)
After-hours: May 9, 2025, 7:44 PM EDT
Fate Therapeutics Employees
Fate Therapeutics had 181 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
181
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$75,309
Profits / Employee
-$1,029,072
Market Cap
119.19M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
FATE News
- 1 day ago - Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector - Seeking Alpha
- 7 days ago - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting - GlobeNewsWire
- 25 days ago - Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) - GlobeNewsWire
- 2 months ago - Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates - GlobeNewsWire
- 2 months ago - Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Fate Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap - Seeking Alpha